Clinical Trials Logo

Clinical Trial Summary

This study will randomize CrossFit participants to receive beta-alanine or placebo supplementation for 3 weeks. The study will be double-blind. Performance on the "Fran" test will be completed at baseline and after the 3 week intervention. Respiratory exchange ratio will also be assessed during the performance test at baseline and after 3 weeks.


Clinical Trial Description

Beta-alanine is a nutritional supplement often consumed by people involved in high-intensity sports that involve substantial lactic acidosis. If consumed on a regular basis, it improves muscle buffering capacity and exercise performance during high-intensity moderate-duration events. CrossFit involves competitions that are high in intensity and moderate duration and many elite CrossFit athletes have reported taking beta-alanine as a supplement. It has never however been evaluated in a research study for its affect on CrossFit performance. The purpose of the study is therefore to assess the effects of beta-alanine supplementation on CrossFit performance. A maximum of 30 CrossFit participants will participate in this randomized double-blind parallel groups study. Participants will be randomized to receive 6.4 g/d beta-alanine or maltodextrin placebo for 3 weeks. At baseline and after the intervention, participants will complete a "Fran" test, which involves performing sets of repeated dumbbell thrusters alternating with chin-ups. The performance measure is the time to complete the test. During the test, respiratory exchange ratio will be assessed to indirectly assess acidosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05772988
Study type Interventional
Source University of Saskatchewan
Contact
Status Completed
Phase N/A
Start date March 15, 2023
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03980678 - Lithothamnion Species on Blood Lactate During Exhaustive Exercise in Trained Cyclists N/A